Endurant Capital Management LP - Q3 2019 holdings

$279 Million is the total value of Endurant Capital Management LP's 49 reported holdings in Q3 2019. The portfolio turnover from Q2 2019 to Q3 2019 was 74.0% .

 Value Shares↓ Weighting
RCM BuyR1 RCM INC$21,244,000
+103.3%
2,378,963
+186.3%
7.62%
+85.0%
ZBH BuyZIMMER BIOMET HLDGS INC$20,933,000
+62.2%
152,496
+39.1%
7.51%
+47.6%
SPY NewSPDR S&P 500 ETF TRput$19,646,00066,200
+100.0%
7.05%
HCA BuyHCA HEALTHCARE INC$18,033,000
+205.8%
149,755
+243.3%
6.47%
+178.4%
OXFD BuyOXFORD IMMUNOTEC GLOBAL PLC$16,454,000
+90.0%
989,436
+57.2%
5.90%
+73.0%
LH BuyLABORATORY CORP AMER HLDGS$14,949,000
+4.3%
88,983
+7.3%
5.36%
-5.1%
BMY BuyBRISTOL MYERS SQUIBB CO$14,804,000
+278.2%
291,925
+238.3%
5.31%
+244.3%
JNJ NewJOHNSON & JOHNSON$13,897,000107,413
+100.0%
4.99%
PRAH BuyPRA HEALTH SCIENCES INC$12,583,000
+30.6%
126,809
+30.5%
4.52%
+18.9%
ABBV BuyABBVIE INC$12,267,000
+89.5%
162,007
+82.0%
4.40%
+72.5%
CI BuyCIGNA CORP NEW$10,945,000
+12.8%
72,109
+17.1%
3.93%
+2.7%
CRL NewCHARLES RIV LABS INTL INC$9,926,00074,986
+100.0%
3.56%
ABC BuyAMERISOURCEBERGEN CORP$8,686,000
+38.6%
105,501
+43.5%
3.12%
+26.1%
SellEVOLENT HEALTH INCnote 2.000%12/0$7,965,000
+60.1%
90,960
-98.4%
2.86%
+45.8%
ZTS NewZOETIS INCcl a$7,600,00060,999
+100.0%
2.73%
WMGI SellWRIGHT MED GROUP N V$6,218,000
-43.9%
301,391
-19.0%
2.23%
-49.0%
ANTM NewANTHEM INC$6,160,00025,657
+100.0%
2.21%
BDX NewBECTON DICKINSON & CO$5,581,00022,061
+100.0%
2.00%
IART BuyINTEGRA LIFESCIENCES HLDGS C$5,059,000
+111.5%
84,225
+96.7%
1.82%
+92.6%
HAE NewHAEMONETICS CORP$4,111,00032,594
+100.0%
1.48%
SIEN SellSIENTRA INC$3,434,000
-56.6%
529,950
-58.8%
1.23%
-60.6%
SNY SellSANOFIsponsored adr$3,113,000
-40.4%
67,200
-44.3%
1.12%
-45.7%
NCNA NewNUCANA PLCsponsored adr$2,785,000384,700
+100.0%
1.00%
FATE NewFATE THERAPEUTICS INC$2,590,000166,782
+100.0%
0.93%
BIO BuyBIO RAD LABS INCcl a$2,299,000
+96.8%
6,910
+85.0%
0.82%
+79.3%
GWPH SellGW PHARMACEUTICALS PLCads$1,970,000
-37.2%
17,130
-5.9%
0.71%
-42.9%
ACRS BuyACLARIS THERAPEUTICS INC$1,911,000
-46.4%
1,769,785
+8.6%
0.69%
-51.2%
INSP NewINSPIRE MED SYS INC$1,880,00030,805
+100.0%
0.68%
SDC NewSMILEDIRECTCLUB INC$1,851,000133,388
+100.0%
0.66%
FLDM NewFLUIDIGM CORP DEL$1,832,000395,701
+100.0%
0.66%
TAK SellTAKEDA PHARMACEUTICAL CO LTDsponsored ads$1,587,000
-90.4%
92,273
-90.1%
0.57%
-91.2%
IOVA SellIOVANCE BIOTHERAPEUTICS INC$1,566,000
-63.1%
86,069
-50.3%
0.56%
-66.4%
 SENSEONICS HLDGS INCnote 5.250% 2/0$1,470,000
-4.5%
1,500,0000.0%0.53%
-13.0%
IIN SellINTRICON CORP$1,430,000
-84.3%
73,543
-81.1%
0.51%
-85.7%
AZN SellASTRAZENECA PLCsponsored adr$1,383,000
-73.2%
31,031
-75.1%
0.50%
-75.6%
CNMD NewCONMED CORP$1,261,00013,112
+100.0%
0.45%
LQDA SellLIQUIDIA TECHNOLOGIES INC$1,132,000
-69.8%
317,993
-32.2%
0.41%
-72.5%
HUM SellHUMANA INC$997,000
-86.5%
3,899
-86.0%
0.36%
-87.7%
PETQ NewPETIQ INC$936,00034,354
+100.0%
0.34%
ATRC SellATRICURE INC$858,000
-86.9%
34,391
-84.3%
0.31%
-88.0%
EHC SellENCOMPASS HEALTH CORP$753,000
-89.6%
11,892
-89.6%
0.27%
-90.6%
AXNX NewAXONICS MODULATION TECH INC$747,00027,759
+100.0%
0.27%
ACHC NewACADIA HEALTHCARE COMPANY IN$743,00023,918
+100.0%
0.27%
PRTA NewPROTHENA CORP PLC$677,00086,407
+100.0%
0.24%
XENT SellINTERSECT ENT INC$643,000
-89.6%
37,815
-86.0%
0.23%
-90.5%
GNCA SellGENOCEA BIOSCIENCES INC$546,000
-51.9%
188,128
-35.1%
0.20%
-56.2%
APLS NewAPELLIS PHARMACEUTICALS INC$537,00022,281
+100.0%
0.19%
NTGN SellNEON THERAPEUTICS INC$332,000
-85.0%
193,052
-58.5%
0.12%
-86.3%
ATNM SellACTINIUM PHARMACEUTICALS INC$311,000
-49.0%
1,354,172
-45.4%
0.11%
-53.3%
ADVM ExitADVERUM BIOTECHNOLOGIES INC$0-31,869
-100.0%
-0.15%
TBIO ExitTRANSLATE BIO INC$0-38,772
-100.0%
-0.19%
GLYC ExitGLYCOMIMETICS INC$0-42,271
-100.0%
-0.20%
ALGN ExitALIGN TECHNOLOGY INC$0-1,962
-100.0%
-0.21%
SRPT ExitSAREPTA THERAPEUTICS INC$0-3,753
-100.0%
-0.22%
MD ExitMEDNAX INC$0-39,401
-100.0%
-0.39%
TNDM ExitTANDEM DIABETES CARE INC$0-19,579
-100.0%
-0.50%
SIBN ExitSI BONE INC$0-65,216
-100.0%
-0.52%
MRNS ExitMARINUS PHARMACEUTICALS INC$0-362,189
-100.0%
-0.59%
GRTS ExitGRITSTONE ONCOLOGY INC$0-143,752
-100.0%
-0.63%
DVA ExitDAVITA INC$0-32,566
-100.0%
-0.72%
OSMT ExitOSMOTICA PHARMACEUTICALS PLC$0-514,239
-100.0%
-0.77%
SGRY ExitSURGERY PARTNERS INC$0-287,720
-100.0%
-0.92%
NVRO ExitNEVRO CORP$0-63,394
-100.0%
-1.62%
XRAY ExitDENTSPLY SIRONA INC$0-82,813
-100.0%
-1.90%
VCRA ExitVOCERA COMMUNICATIONS INC$0-203,000
-100.0%
-2.56%
AVDR ExitAVEDRO INC$0-357,942
-100.0%
-2.77%
IRTC ExitIRHYTHM TECHNOLOGIES INC$0-103,448
-100.0%
-3.22%
ExitFLUIDIGM CORP DELnote 2.750% 2/0$0-8,756,000
-100.0%
-3.31%
Original filings

The following EDGAR filing(s) were analyzed to create this report:

  • View 13F-HR/A filed 2019-11-25
Signatures

The EDGAR filing(s) were signed by:

Top long-term holdings
NameQuarters ownedLatest quarter ownedMax weighting
LABORATORY CORP AMER HLDGS31Q2 20238.7%
ELEVANCE HEALTH INC29Q3 20238.8%
BECTON DICKINSON & CO28Q2 20239.8%
MCKESSON CORP27Q1 20234.4%
CENCORA INC26Q3 20235.9%
HOLOGIC INC24Q3 20237.5%
JOHNSON & JOHNSON24Q4 20215.5%
ZIMMER HLDGS INC23Q3 20237.5%
BOSTON SCIENTIFIC CORP22Q3 20235.5%
DAVITA INC22Q1 20214.9%

View Endurant Capital Management LP's complete holdings history.

Latest significant ownerships (13-D/G)
Endurant Capital Management LP Q3 2019 significant holdings filed using form 13D/G when ownership exceeds 5% of a company's total stock issue.
FiledShares Percentage
AZIYO BIOLOGICS, INC.March 21, 2023576,2534.9%
Oxford Immunotec Global PLCSold outFebruary 17, 202100.0%

View Endurant Capital Management LP's complete significant-ownership history.

Latest filings
TypeFiled
SC 13D/A2024-04-10
13F-HR2024-02-14
13F-HR2023-11-14
SC 13D/A2023-09-08
13F-HR2023-08-14
3/A2023-05-24
13F-HR2023-05-15
32023-05-15
SC 13D2023-05-15
SC 13G/A2023-03-21

View Endurant Capital Management LP's complete filings history.

Compare quarters

Issues

The following issues were detected while analyzing the report:

  • The reported has been restated
  • The reported has been amended

Export Endurant Capital Management LP's holdings